Compendium of Cancer Genome Aberrations

BRST5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 39: Line 39:
----
----
|-
|-
|Usual Ductal Hyperplasia
|Usual ductal hyperplasia
|Disease
|Disease
|
|
Line 50: Line 50:
|
|
|-
|-
|Columnar Cell Lesions, Including Flat Epithelial Atypia||Disease||
|Columnar cell lesions, including flat epithelial atypia||Disease||
|
|
|
|
Line 59: Line 59:
|
|
|-
|-
|Atypical Ductal Hyperplasia||Disease||
|Atypical ductal hyperplasia||Disease||
|
|
|
|
Line 68: Line 68:
|
|
|-
|-
|Sclerosing Adenosis||Disease||
|Sclerosing adenosis||Disease||
|
|
|
|
Line 77: Line 77:
|
|
|-
|-
|Apocrine Adenosis and Adenoma||Disease||
|Apocrine adenosis and adenoma||Disease||
|
|
|
|
Line 86: Line 86:
|
|
|-
|-
|Microglandular Adenosis||Disease||
|Microglandular adenosis||Disease||
|
|
|
|
Line 95: Line 95:
|
|
|-
|-
|Radial Scar/Complex Sclerosing Lesion||Disease||
|Radial scar/complex sclerosing lesion||Disease||
|
|
|
|
Line 104: Line 104:
|
|
|-
|-
|Tubular Adenoma||Disease||
|Tubular adenoma||Disease||
|
|
|
|
Line 113: Line 113:
|
|
|-
|-
|Lactating Adenoma||Disease||
|Lactating adenoma||Disease||
|
|
|
|
Line 122: Line 122:
|
|
|-
|-
|Ductal Adenoma||Disease||
|Ductal adenoma||Disease||
|
|
|
|
Line 131: Line 131:
|
|
|-
|-
|Pleomorphic Adenoma||Disease||
|Pleomorphic adenoma||Disease||
|
|
|
|
Line 149: Line 149:
|
|
|-
|-
|Malignant Adenomyoepithelioma||Disease||
|Malignant adenomyoepithelioma||Disease||
|
|
|
|
Line 158: Line 158:
|
|
|-
|-
|Intraductal Papilloma||Disease||
|Intraductal papilloma||Disease||
|
|
|
|
Line 167: Line 167:
|
|
|-
|-
|Papillary Ductal Carcinoma In Situ||Disease||
|Papillary ductal carcinoma in situ||Disease||
|
|
|
|
Line 176: Line 176:
|
|
|-
|-
|Encapsulated Papillary Carcinoma||Disease||
|Encapsulated papillary carcinoma||Disease||
|
|
|
|
Line 185: Line 185:
|
|
|-
|-
|Solid Papillary Carcinoma (In Situ and Invasive)||Disease||
|Solid papillary carcinoma (in situ and invasive)||Disease||
|
|
|
|
Line 194: Line 194:
|
|
|-
|-
|Invasive Papillary Carcinoma||Disease||
|Invasive papillary carcinoma||Disease||
|
|
|
|
Line 203: Line 203:
|
|
|-
|-
|Atypical Lobular Hyperplasia||Disease||
|Atypical lobular hyperplasia||Disease||
|
|
|
|
Line 212: Line 212:
|
|
|-
|-
|Lobular Carcinoma In Situ||Disease||
|Lobular carcinoma in situ||Disease||
|
|
|
|
Line 221: Line 221:
|
|
|-
|-
|Ductal Carcinoma In Situ||Disease||
|Ductal carcinoma in situ||Disease||
|
|
|
|
Line 230: Line 230:
|
|
|-
|-
|Invasive Breast Carcinoma of No Special Type||Disease||
|Invasive breast carcinoma of no special type||Disease||
|
|
|
|
Line 239: Line 239:
|
|
|-
|-
|Microinvasive Carcinoma||Disease||
|Microinvasive carcinoma||Disease||
|
|
|
|
Line 248: Line 248:
|
|
|-
|-
|Invasive lobular Carcinoma||Disease||
|Invasive lobular carcinoma||Disease||
|
|
|
|
Line 257: Line 257:
|
|
|-
|-
|Tubular Carcinoma||Disease||
|Tubular carcinoma||Disease||
|
|
|
|
Line 266: Line 266:
|
|
|-
|-
|Cribriform Carcinoma||Disease||
|Cribriform carcinoma||Disease||
|
|
|
|
Line 275: Line 275:
|
|
|-
|-
|Mucinous Carcinoma||Disease||
|Mucinous carcinoma||Disease||
|
|
|
|
Line 284: Line 284:
|
|
|-
|-
|Mucinous Cystadenocarcinoma||Disease||
|Mucinous cystadenocarcinoma||Disease||
|
|
|
|
Line 293: Line 293:
|
|
|-
|-
|Invasive Micropapillary Carcinoma||Disease||
|Invasive micropapillary carcinoma||Disease||
|
|
|
|
Line 302: Line 302:
|
|
|-
|-
|Carcinoma with Apocrine Differentiation||Disease||
|Carcinoma with apocrine differentiation||Disease||
|
|
|
|
Line 311: Line 311:
|
|
|-
|-
|Metaplastic Carcinoma||Disease||
|Metaplastic carcinoma||Disease||
|
|
|
|
Line 320: Line 320:
|
|
|-
|-
|[[BRST5:Acinic Cell Carcinoma|Acinic Cell Carcinoma]]||Disease||Patricija Zot
|[[BRST5:Acinic Cell Carcinoma|Acinic cell carcinoma]]||Disease||Patricija Zot
|2/28/2024
|2/28/2024
|
|
Line 329: Line 329:
|
|
|-
|-
|[[BRST5:Adenoid Cystic Carcinoma|Adenoid Cystic Carcinoma]]||Disease||Katherine Geiersbach / Jun Liao
|[[BRST5:Adenoid Cystic Carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach / Jun Liao
|10/12/02022
|10/12/02022
|11/11/2023
|11/11/2023
Line 338: Line 338:
|2021 template added
|2021 template added
|-
|-
|[[BRST5:Secretory Carcinoma|Secretory Carcinoma]]||Disease||Hui Chen / Morteza Seifi
|[[BRST5:Secretory Carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Morteza Seifi
|10/12/2022
|10/12/2022
|11/11/2023
|11/11/2023
Line 347: Line 347:
|2021 template added
|2021 template added
|-
|-
|Mucoepidermoid Carcinoma||Disease||
|Mucoepidermoid carcinoma||Disease||
|
|
|
|
Line 356: Line 356:
|
|
|-
|-
|Polymorphous Adenocarcinoma||Disease||
|Polymorphous adenocarcinoma||Disease||
|
|
|
|
Line 365: Line 365:
|
|
|-
|-
|[[BRST5:Tall Cell Carcinoma with Reversed Polarity|Tall Cell Carcinoma with Reversed Polarity]]||Disease||H. Evin Gulbahce
|[[BRST5:Tall Cell Carcinoma with Reversed Polarity|Tall cell carcinoma with reversed polarity]]||Disease||H. Evin Gulbahce
|8/11/2023
|8/11/2023
|10/11/2023
|10/11/2023
Line 374: Line 374:
|2021 template added
|2021 template added
|-
|-
|Neuroendocrine Tumour||Disease||
|Neuroendocrine tumour||Disease||
|
|
|
|
Line 383: Line 383:
|
|
|-
|-
|Neuroendocrine Carcinoma||Disease||
|Neuroendocrine carcinoma||Disease||
|
|
|
|
Line 430: Line 430:
|2021 template added
|2021 template added
|-
|-
|[[BRST5:Phyllodes Tumour|Phyllodes Tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
|[[BRST5:Phyllodes Tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
|8/11/2023
|8/11/2023
|11/11/2023
|11/11/2023
Line 459: Line 459:
----
----
|-
|-
|Syringomatous Tumour||Disease||
|Syringomatous tumour||Disease||
|
|
|
|
Line 468: Line 468:
|
|
|-
|-
|Nipple Adenoma||Disease||
|Nipple adenoma||Disease||
|
|
|
|
Line 477: Line 477:
|
|
|-
|-
|Paget disease of the Breast||Disease||
|Paget disease of the breast||Disease||
|
|
|
|
Line 524: Line 524:
|
|
|-
|-
|Atypical Vascular Lesions||Disease||
|Atypical vascular lesions||Disease||
|
|
|
|
Line 533: Line 533:
|
|
|-
|-
|Postradiation Angiosarcoma of the Breast||Disease||
|Postradiation angiosarcoma of the breast||Disease||
|
|
|
|
Line 542: Line 542:
|
|
|-
|-
|Primary Angiosarcoma of the Breast||Disease||
|Primary angiosarcoma of the breast||Disease||
|
|
|
|
Line 551: Line 551:
|
|
|-
|-
|Nodular Fasciitis||Disease||
|Nodular fasciitis||Disease||
|
|
|
|
Line 569: Line 569:
|
|
|-
|-
|Desmoid Fibromatosis||Disease||
|Desmoid fibromatosis||Disease||
|
|
|
|
Line 578: Line 578:
|
|
|-
|-
|[[BRST5:Inflammatory Myofibroblastic Tumour|Inflammatory Myofibroblastic Tumour]]||Disease||Yajuan Liu
|[[BRST5:Inflammatory Myofibroblastic Tumour|Inflammatory myofibroblastic tumour]]||Disease||Yajuan Liu
|8/11/2023
|8/11/2023
|11/11/2023
|11/11/2023
Line 605: Line 605:
|
|
|-
|-
|Granular Cell Tumour||Disease||
|Granular cell tumour||Disease||
|
|
|
|
Line 659: Line 659:
|
|
|-
|-
|Pseudoangiomatous Stromal Hyperplasia||Disease||
|Pseudoangiomatous stromal hyperplasia||Disease||
|
|
|
|
Line 688: Line 688:
----
----
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease||
|
|
|
|
Line 697: Line 697:
|
|
|-
|-
|Follicular Lymphoma||Disease||
|Follicular lymphoma||Disease||
|
|
|
|
Line 706: Line 706:
|
|
|-
|-
|Diffuse Large B-cell Lymphoma||Disease||
|Diffuse large B-cell lymphoma||Disease||
|
|
|
|
Line 715: Line 715:
|
|
|-
|-
|Burkitt Lymphoma||Disease||
|Burkitt lymphoma||Disease||
|
|
|
|
Line 724: Line 724:
|
|
|-
|-
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||
|Breast implant-associated anaplastic large cell lymphoma||Disease||
|
|
|
|
Line 762: Line 762:
|
|
|-
|-
|Carcinoma In Situ||Disease||
|Carcinoma in situ||Disease||
|
|
|
|
Line 771: Line 771:
|
|
|-
|-
|Invasive Carcinoma||Disease||
|Invasive carcinoma||Disease||
|
|
|
|
Line 780: Line 780:
|
|
|-
|-
|Metastases to the Breast||Disease||
|Metastases to the breast||Disease||
|
|
|
|
Line 809: Line 809:
----
----
|-
|-
|BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|BRCA1/2-associated hereditary breast and ovarian cancer syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 818: Line 818:
|N/A
|N/A
|-
|-
|Cowden Syndrome||Disease||
|Cowden syndrome||Disease||
|
|
|
|
Line 827: Line 827:
|NOT YET CREATED (not in GTS5) - See page "[[DIG5:Cowden syndrome|Cowden Syndrome]]" in DIG5 book. Will later add breast book link redirecting to this DIG5 book page (need to correlate with related volunteer page - [[DIG5:Volunteer Assignments and Opportunities]]).
|NOT YET CREATED (not in GTS5) - See page "[[DIG5:Cowden syndrome|Cowden Syndrome]]" in DIG5 book. Will later add breast book link redirecting to this DIG5 book page (need to correlate with related volunteer page - [[DIG5:Volunteer Assignments and Opportunities]]).
|-
|-
|Ataxia-Telangiectasia||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|Ataxia-telangiectasia||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 836: Line 836:
|N/A
|N/A
|-
|-
|Li-Fraumeni Syndrome, TP53-Associated||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|Li-Fraumeni syndrome, TP53-associated||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 845: Line 845:
|N/A
|N/A
|-
|-
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni Syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 854: Line 854:
|N/A
|N/A
|-
|-
|CDH1-Associated Breast Cancer||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|CDH1-associated breast cancer||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 863: Line 863:
|N/A
|N/A
|-
|-
|PALB2-Associated Cancers||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|PALB2-associated cancers||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 872: Line 872:
|N/A
|N/A
|-
|-
|Peutz-Jeghers Syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|Peutz-Jeghers syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 881: Line 881:
|N/A
|N/A
|-
|-
|Neurofibromatosis Type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
|Neurofibromatosis type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
|
|
|
|
Line 890: Line 890:
|NOT YET CREATED - See page "[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis Type 1 (NF1)]]" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - [[GTS5:Volunteer Assignments and Opportunities]]).
|NOT YET CREATED - See page "[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis Type 1 (NF1)]]" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - [[GTS5:Volunteer Assignments and Opportunities]]).
|-
|-
|[[BRST5:Polygenic Component of Breast Cancer Susceptibility|Polygenic Component of Breast Cancer Susceptibility]]
|[[BRST5:Polygenic Component of Breast Cancer Susceptibility|Polygenic component of breast cancer susceptibility]]
|Disease
|Disease
|Xiaolin Hu
|Xiaolin Hu
Retrieved from "https://test.ccga.io/index.php/BRST5:Volunteer_Assignments_and_Opportunities"